Skip to main content
712 search results for:

Breast cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 16-08-2023 | Breast cancer | News | Article

    AI-supported mammography matches standard screen-detected breast cancer rate

    Preliminary MASAI trial results indicate that AI-supported mammography has a similar rate of breast cancer detection to standard double reading while reducing the screen-reading workload.

  2. 05-06-2023 | Breast cancer | Conference coverage | Article
    ASCO 2023

    Adjuvant ribociclib reduces recurrence risk in early breast cancer

    Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

  3. 06-04-2023 | Breast cancer | News | Article

    Anthracycline-related heart failure risk highlighted for breast cancer, lymphoma survivors

    Research has confirmed that congestive heart failure is significantly more common in people given an anthracycline to treat breast cancer or lymphoma than among those given other types of chemotherapy, even after adjusting for confounding factors.

  4. 23-03-2023 | Breast cancer | News | Article

    Progestagen-only contraceptives linked to ‘slight’ increase in breast cancer risk

    The current or recent use of progestagen-only contraceptives is associated with an increased risk for developing breast cancer, irrespective of the mode of delivery, suggests research published in PLOS Medicine .

  5. 01-03-2023 | Breast cancer | News | Article

    PRIME II ‘extremely reassuring’ on radiotherapy omission in older women with early breast cancer

    The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.

  6. 06-02-2023 | Breast cancer | News | Article

    Disparities exist in care of breast cancer patients from minority sexual orientation, gender groups

    US research points to disparities in the diagnosis, treatment, and outcomes of breast cancer in people belonging to minority groups with respect to sexual orientation and gender identity.

  7. 26-10-2022 | Breast cancer | News | Article

    Minimal access breast surgery ‘valid’ option for early breast cancer

    Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.

  8. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

    Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

  9. 08-12-2022 | SABCS 2022 | Conference coverage | Article

    First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

    Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

  10. 09-12-2022 | SABCS 2022 | Conference coverage | Article

    Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

    Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

  11. 25-11-2022 | Breast cancer | News | Article

    GIM2 defines ‘optimal’ high-risk early breast cancer adjuvant chemotherapy

    End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

  12. 12-12-2022 | SABCS 2022 | Conference coverage | Article

    Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

    The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

  13. 18-11-2022 | Breast cancer | News | Article

    Novel nonhormonal agent shows promise for hot flashes, night sweats in patients with breast cancer

    The oral nonhormonal agent Q-122 appears to be an efficacious and well tolerated option for the control of vasomotor symptoms in women with breast cancer receiving adjuvant endocrine therapy, suggest phase 2 trial data.

  14. 10-08-2022 | Image

    Early breast cancer

  15. 10-10-2022 | Breast cancer | News | Article

    Lower pCR rate highlighted for male breast cancer after neoadjuvant chemotherapy

    Men are less likely than women to achieve a pathologic complete response to neoadjuvant chemotherapy for invasive, nonmetastatic breast cancer, US researchers report.

  16. 06-10-2022 | Breast cancer | News | Article

    Meta-analysis shows link between margin involvement and poor breast cancer outcomes

    Involved or close pathologic margins after breast conserving surgery are associated with an increased risk for distant recurrence and mortality in women with early-stage invasive breast cancer, indicates a meta-analysis.

  17. 03-10-2022 | Breast cancer | News | Article

    High IL-6, CRP may predict increased frailty after breast cancer chemotherapy

    Clinically fit older women with early breast cancer are more likely to experience a chemotherapy-induced decline in frailty status if they have high pretreatment levels of interleukin-6 and C-reactive protein, research shows.

  18. 09-09-2022 | ESMO 2022 | Conference coverage | Article

    Sacituzumab govitecan boosts HR+, HER2– advanced breast cancer OS

    Among people with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, sacituzumab govitecan is associated with significantly improved overall survival relative to standard of care, show data from TROPiCS-02.

  19. 02-09-2022 | Breast cancer | News | Article

    Fertility preservation not linked to higher breast cancer relapse, mortality risk

    Women who undergo hormonal or nonhormonal fertility preservation procedures following breast cancer diagnosis are not at increased risk for relapse or breast cancer-specific mortality, Swedish study findings indicate.

  20. play
    12-09-2022 | ESMO 2022 | Conference coverage | Video

    TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer

    Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.